Literature DB >> 29304336

Turning up the Heat with Therapeutic Epigenome Editing.

Alexandra Zezulin1, Kiran Musunuru2.   

Abstract

CRISPR-Cas9 has been touted for therapeutic genome editing, but limitations include inefficient correction of disease-causing mutations and off-target mutagenesis. In the latest issue of Cell, Liao et al. (2017) show that a modified version of CRISPR-Cas9 can target and activate key therapeutic genes in vivo without altering DNA sequence identity.
Copyright © 2017 Elsevier Inc. All rights reserved.

Mesh：

Year:  2018        PMID： 29304336     DOI： 10.1016/j.stem.2017.12.013

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  4 in total

Review 1.  Novel Epigenetic Techniques Provided by the CRISPR/Cas9 System.

Authors:  Nina Xie; Yafang Zhou; Qiying Sun; Beisha Tang
Journal:  Stem Cells Int       Date:  2018-07-08       Impact factor: 5.443

Review 2.  CRISPR/dCas9 platforms in plants: strategies and applications beyond genome editing.

Authors:  Mahdi Moradpour; Siti Nor Akmar Abdulah
Journal:  Plant Biotechnol J       Date:  2019-09-03       Impact factor: 9.803

Review 3.  Moving Beyond DNA Sequence to Improve Plant Stress Responses.

Authors:  Faisal Saeed; Usman Khalid Chaudhry; Allah Bakhsh; Ali Raza; Yasir Saeed; Abhishek Bohra; Rajeev K Varshney
Journal:  Front Genet       Date:  2022-04-19       Impact factor: 4.772

4.  Ethics and regulatory considerations for the clinical translation of somatic cell human epigenetic editing.

Authors:  Nikolajs Zeps; Tamra Lysaght; Ruth Chadwick; Alexandre Erler; Roger Foo; Simona Giordano; Poh San Lai; G Owen Schaefer; Vicki Xafis; Wei Leong Chew; Jeremy Sugarman
Journal:  Stem Cell Reports       Date:  2021-07-01       Impact factor: 7.765
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.